Therapy should include either belimumab or a calcineurin inhibitor, plus one or more conventional medications such as ...

Immunological tests can differentiate proliferative from non-proliferative lupus nephritis, but anti-C1q antibodies and urinary erythrocytes have the best predictive power to dist ...

DelveInsight's "LUPKYNIS Market Size, Forecast, and Market Insight Report" highlights the details around LUPKYNIS, the first ...

A global survey conducted by the World Lupus Federation reveals that 47% of people living with lupus report kidney ...

Lupus presents unique challenges, particularly for patients with lupus nephritis — a severe form of the condition that affects kidney function and quality of life. Current treatments often come with ...

New data highlights urgent need for improved education and diagnosis of lupus nephritis (lupus-related kidney disease), a serious complication of lupus A global survey conducted by the World Lupus ...

As a novel calcineurin inhibitor with proven efficacy in improving renal outcomes, LUPKYNIS addresses a high unmet medical need. With increasing awareness, supportive guidelines, and potential ...

Anti-C1q antibodies are a promising marker for the diagnosis and management of lupus nephritis. Immunological tests can differentiate proliferative from non-proliferative lupus nephritis ...

New data highlights urgent need for improved education and diagnosis of lupus nephritis (lupus-related kidney disease), a serious complication of lupus WASHINGTON, May 6, 2025 /PRNewswire/ -- A ...